01:18 PM EDT, 03/10/2025 (MT Newswires) -- Tevogen Bio ( TVGN ) said Monday it filed a new patent with the US Patent and Trademark Office for its T cell vaccine that is currently under development.

The company said the vaccine's design aims to use its Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate a T cell response, unlike vaccines that mainly induce a B cell response.

Tevogen Bio ( TVGN ) said that similar to its lead product candidate TVGN 489, the vaccine can target the entire viral genome, helping to mitigate a risk posed by mutations.

The company's shares were down over 5% in recent trading.

Price: 1.08, Change: -0.06, Percent Change: -5.09